Dose-response relationship and mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhea in rats

Digestive Diseases and Sciences

Volumn 48, Issue 4, 2003, Pages 770-774

  Girard, Philippe ^a   Pansart, Yannick ^a   Lorette, Ingrid ^a   Gillardin, Jean Marie ^a  

^a Service de Pharmacologie   (France)

Author keywords

Castor oil; Diarrhea; Nitric oxide; Saccharomyces boulardii; Yeast

Indexed keywords

ARGININE; CASTOR OIL; NALOXONE; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; INGESTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RAT; SACCHAROMYCES BOULARDII; YEAST;

ANIMALS; ANTIDIARRHEALS; ARGININE; CASTOR OIL; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FUNGAL VACCINES; INDOMETHACIN; LOPERAMIDE; MALE; NALOXONE; PROBIOTICS; RATS; RATS, WISTAR; SACCHAROMYCES; WATER-ELECTROLYTE BALANCE;

EID: 0037380284     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022801228938     Document Type: Article

References (36)

1. Elmer GW, Surawicz CM, McFarland LV: Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 275:870-876, 1996
2. McFarland LV, Bernasconi P: Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microb Ecol Health Dis 6:157-171, 1993
3. Periti P, Tonelli F: Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii. J Chemother 1:1-20, 2001
4. Massot J, Sanchez O, Couchy R, Astoin J, Parodi AL: Bacterio-pharmacological activity of Saccharomyces boulardii in clindamycin-induced colitis in the hamster. Arzneimittelforschung 34:794-797, 1984
5. Toothaker RD, Elmer GW: Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii. Antimicrob Agents Chemother 26:552-556, 1984
6. Corthier G, Dubos F, Ducluzeau R: Prevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardii. Can J Microbiol 32:894-896, 1986
7. Elmer GW, Corthier G: Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventive agent in gnotobiotic mice. Can J Microbiol 37:315-317, 1991
8. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, Van Belle G: Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 96:981-988, 1989
9. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL: Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 90:439-448, 1998
10. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KF, Cox JL, Noorani Z: A randomised placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271:224-226, 1994
11. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmarker S, Bowen K, Borjal D, Elmer GW: The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31:1012-1017, 2000
12. Buts JP, Corthier G, Delmee M: Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr 16:419-425, 1993
13. Plein K, Hotz J: Therapeutic effect of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea. A pilot study. Z Gastroenterol 31:129-134, 1993
14. Kollaritsch H, Hoist H, Grobara O, Wiedermann G: Prevention of traveller's diarrhea. Results of a placebo-controlled double-blind study. Fortschr Med 111:152-156, 1993
15. Cetina-Sauri G, Sierra Basto G: Evaluation thérapeutique de Saccharomyces boulardii chez des enfants souffrant de diarrhée aiguë. Ann Pediatr (Paris) 41:397-400, 1994
16. Chassany O, Michaux A, Bergmann JF: Drug-induced diarrhea. Drug Saf 22:53-72, 2000
17. Gaginella TS, Bass P: Laxatives: an update on mechanism of action. Life Sci 23:1001-1010, 1978
18. Awouters F, Niemegeers CJE, Lenaerts FM, Janssen, PAJ: Delay of castor oil diarrhea in rats: a new way to evaluate inhibitors of prostaglandin biosynthesis. J Pharm Pharmacol 30:41-45, 1978
19. Hedge SS, Moy TM, Perry MR, Loeb M, Eglen RM: Evidence for the involvement of 5-hydroxytryptamine 4 receptors in 5-hydroxytryptophan-induced diarrhea in mice. J Pharmacol Exp Ther 271:741-747, 1994
20. Niemegeers CJE, Colpaert FC, Awouters FHL: Pharmacology and antidiarrheal effect of loperamide. Drug Dev Res 1:1-20, 1981
21. Awouters F, Niemegeers CJE, Janssen PAJ: Pharmacology of antidiarrheal drugs. Annu Rev Pharmacol Toxicol 23:279-301, 1983
22. Pothoulakis C, Kelly CP, Joshi MA, Gao N, O'Keane CJ, Castagliuolo I, Lamont JT: Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104:1108-1115, 1993
23. Izadnia F, Tse Wong C, Kocoshis SA: Brewer's yeast and Saccharomyces boulardii both attenuate Clostridium difficile-induced colonic secretion in the rat. Dig Dis Sci 43:2055-2060, 1998
24. Blehaut H, Massot J, Elmer GW, Levy RH: Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos 10:353-364, 1989
25. Boddy AV, Elmer GW, McFarland LV, Levy RH: Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats. Pharm Res 8:796-800, 1991
26. Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH: Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res 10:1615-1619, 1993
27. Krammer M, Karbach U: Antidiarrheal action of the yeast Saccharomyces boulardii in the rat small and large intestine by stimulating chloride absorption. Z Gastroenterol 31(suppl 4):73-77, 1993
28. Vidon N, Huchet B, Rambaud JC: Influence de Saccharomyces boulardii sur la sécrétion jéjunale induite chez le rat par la toxine cholérique. Gastroenterol Clin Biol 10:13-16, 1986
29. Czerucka D, Roux I, Rampal P: Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′,5′-cyclic monophosphate induction in intestinal cells. Gastroenterology 106:65-72, 1994
30. - secretion in T84 cells. Dig Dis Sci 44:2359-2368, 1999
31. Croci T, Landi M, Edmonts-Alt X, Le Fur G, Maffrand JP, Manara L: Role of tachykinins in castor oil diarrhea in rats. Br J Pharmacol 121:375-380, 1997
32. Mascolo N, Izzo AA, Barbato F, Capasso F: Inhibitors of nitric oxide synthetase prevent castor-oil-induced diarrhea in the rat. Br J Pharmacol 108:861-864, 1993
33. Izzo AA, Mascolo N, Capasso F: Nitric oxide as a modulator of intestinal water and electrolyte transport. Dig Dis Sci 43:1605-1620, 1998
34. Beubler E, Juan H: Effect of ricinoleic acid and other laxatives on net water flux and prostaglandin E release by rat colon. J Pharm Pharmacol 31:681-685, 1979
35. Mascolo N, Izzo AA, Gaginella TS, Capasso F: Relationship between nitric oxide and platelet-activating factor in castor oil-induced mucosal injury in the rat duodenum. Naunyn Schmiedebergs Arch Pharmacol 353:608-684, 1996
36. Guslandi M, Mezzi G, Sorghi M, Testoni PA: Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45:1462-1464, 2000